ICMR Will Get Royalty of 5% from Sale of Bharat Biotech’s Covaxin. Here’s Why It’s Raising Eyebrows

The intellectual property governing the use of Covaxin, jointly developed by Bharat Biotech and the ICMR, was “shared” and that is why it would receive royalty payments.

Similar Articles

Most Popular